Close

Welcome back to Stockhouse
Member Sign In

Email or Username:
Password:
Close

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Quote  |  Bullboard  |  News  |  Opinion  |  Level II  |  Charts  |  Profile  |  Financials  |  Options  |  Price History  |  Analysts  |  Earnings  |  Insiders

Theratechnologies Inc T.TH

Sector: Healthcare | Sub-Sector: Biotechnology
Alternate Symbol(s):  THERF

Theratechnologies Inc is a pharmaceutical company addressing unmet medical needs in metabolic disorders. EGRIFTA is its registered trademark in the USA and it is used to commercialize its first product using its internally developed compound, tesamorelin.
Price: $1.03 | Change: +$0.05 | %Change: +5.10%
Volume: 296,563 | Day High/Low: 1.04/1.01 | 52 Week High/Low: 1.09/0.325
View modes: 
0 stars

RE:RE:RE:RE:RE:RE:Hi Palinc2000...

yes looks very interesting .. they had peak sales of 30 million plus.. stock used to trade a fair bit higher.. in for a bit.. maybe more on a pullback..\  rate and reply
0 stars

RE:RE:RE:RE:RE:Hi Palinc2000...

Just finished having a second look at their financials along with Power Point Presentation projected revenue growth in the pipeline look's promising for 2015 for starters. Like you say Palinc proof...read more
0 stars

RE:RE:RE:RE:RE:Hi Palinc2000...

the 2015 1st quarter was nearly over at the time this PR was issued so there will be no surprise when the first quarter results come out in a few weeks .....what needs to happen is a conviction that...read more
0 stars

RE:RE:RE:RE:Hi Palinc2000...

Here's another try, exert from MD&A projection revenue growth of 70% to $4,547,500 for Q1 2015 from $2,657,000 in Q4 2014 http://www.sedar.com/GetFile.do?lang=EN&docClass=7&issuerNo=00003190&fileName...read more
0 stars

RE:RE:RE:Hi Palinc2000...

tibutch1 wrote: Thanks Palinc, looking at their MD&A they project strong revenue growth for 2015 and generating enough revenues to cover their operating expenses. As per their projected sales data...read more
0 stars

RE:RE:Hi Palinc2000...

Thanks Palinc, looking at their MD&A they project strong revenue growth for 2015 and generating enough revenues to cover their operating expenses. As per their projected sales data for Q1 2015 it...read more
5 stars

RE:Hi Palinc2000...

I suggest you look at their presentation on the website as a starter The new cost structure appears to have lowered the number of patients required to break even and thus provides tremenfous...read more
0 stars

Hi Palinc2000...

I know you have been around this story way back even before when I first took a position back in late 2006 prior the Swiss company competitor's fiasco results and if you recall I was also around...read more
0 stars

RE:RE:TH halted

This should tell you just how smart this cannacord seller is.  rate and reply
0 stars

RE:Appoved in canada for the 1 mg vial

The ouf is because there were no bad news!!  rate and reply
4.5 stars

Health Canada Approves 1mg/vial Presentation of EGRIFTA(TM)

Theratechnologies Inc. (Theratechnologies) (TSX:TH) is pleased to announce that Health Canada has approved a Supplement to a New Drug Submission for the 1mg/vial presentation of EGRIFTA(TM...read more
0 stars

Appoved in canada for the 1 mg vial

Ouf!!!  rate and reply
0 stars

RE:TH halted

Canaccord selling like mad till the halt Crossing my fingers that the news is not negative  rate and reply
0 stars

TH halted

It has just been halted. A news should follow after closing. It would explain the recent rise.  rate and reply
0 stars

RE:RE:RE:RE:RE:RE:RE:I have a question for the long term holders here...

I am not minimizing anything. I don't know why they are not able to do the 2 mg per vial version correctly. But there is no rocket science there.  rate and reply
0 stars

RE:RE:RE:RE:RE:RE:I have a question for the long term holders here...

You seem to mimimize manufacturing issues Th has not yet been able to produce the 2 mg version for more than a year now  rate and reply
0 stars

RE:RE:RE:RE:RE:I have a question for the long term holders here...

As for any generic a new player will need to see a sufficient market before going in and invest to develop an equivalent version. The more success Thera will get, the more likely they are to attract...read more
0 stars

RE:RE:RE:RE:I have a question for the long term holders here...

2023 not 2013  rate and reply
0 stars

RE:RE:RE:I have a question for the long term holders here...

Could the fact that the manufacturing process appears to be so complicated mitigate the loss of the patent protection in 2013 ? I presume that the generic version would not be produced by the current...read more
0 stars

RE:RE:I have a question for the long term holders here...

You are right about the dedicated sale force.  This very well could have kept the sales from going up more. However, times has changed and you should not simply look at the # of patients.  At that...read more